Centiva Capital LP Purchases New Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Centiva Capital LP acquired a new position in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor acquired 22,160 shares of the company’s stock, valued at approximately $31,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. acquired a new position in Lyell Immunopharma during the third quarter worth approximately $52,000. Erste Asset Management GmbH purchased a new position in shares of Lyell Immunopharma during the third quarter worth approximately $82,000. Intech Investment Management LLC acquired a new position in shares of Lyell Immunopharma in the 3rd quarter valued at $52,000. GSA Capital Partners LLP raised its position in Lyell Immunopharma by 1,285.5% in the 3rd quarter. GSA Capital Partners LLP now owns 354,815 shares of the company’s stock valued at $490,000 after purchasing an additional 329,205 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in Lyell Immunopharma by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 49,238 shares of the company’s stock worth $68,000 after purchasing an additional 19,287 shares during the last quarter. Institutional investors and hedge funds own 66.05% of the company’s stock.

Lyell Immunopharma Stock Performance

Shares of LYEL opened at $0.67 on Friday. The stock has a market capitalization of $196.86 million, a P/E ratio of -0.85 and a beta of -0.45. Lyell Immunopharma, Inc. has a 1 year low of $0.65 and a 1 year high of $3.26. The company’s fifty day moving average is $1.05 and its two-hundred day moving average is $1.45.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.03. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. The firm had revenue of $0.03 million during the quarter. Sell-side analysts predict that Lyell Immunopharma, Inc. will post -0.8 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have commented on LYEL shares. Bank of America lowered shares of Lyell Immunopharma from a “buy” rating to an “underperform” rating and dropped their price objective for the company from $6.00 to $1.00 in a research note on Wednesday, October 30th. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price objective on shares of Lyell Immunopharma in a research report on Tuesday, November 12th.

Lyell Immunopharma Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.